Articles tagged "Kidney transplantation"

2016 American Transplant Congress
Composite Score to Define the Risk of Allograft Loss After Standard-of-Care Treatment of Antibody-Mediated Rejection in Kidney Transplantation.
D. Viglietti,¹ A. Loupy,² J. Duong Van Huyen,² J. Verine,¹ A. Zeevi,³ C. Legendre,² D. Glotz,¹ C. Lefaucheur.¹
¹Saint-Louis Hospital, Paris, France; ²Necker Hospital, Paris, France; ³University of Pittsburgh Medical Center, Pittsburgh.
The development of a reliable surrogate endpoint for allograft survival after AMR treatment is a current unmet need in clinical transplantation (FDA AMR Workshop). We…
2016 American Transplant Congress
Molecular Profiles of Renal Allograft Rejection.
Z. Hajjiri, P. Finn, D. Perkins.
Internal Medicine/Renal Medicine, University of Illinois at Chicago, Chicago, Il.
Introduction: The gold standard for the diagnosis of allograft rejection is the Banff Classification, yet it shows substantial variability among pathologists. Using molecular signatures of…
2016 American Transplant Congress
Is Prolonged Cold Ischemia a Contraindication to Using Kidneys from Acute Kidney Injury Donors?
M. Khan,¹ A. Carrier,¹ H. El-Hennawy,¹ A. Farney,¹ J. Rogers,¹ G. Orlando,¹ A. Reeves-Daniel,² A. Palanisamy,² M. Gautreaux,³ S. Iskandar,³ W. Doares,⁴ S. Kaczmorski,⁴ R. Stratta.¹
¹Surgery, Wake Forest, Winston-Salem, NC; ²Internal Medicine, Wake Forest, Winston-Salem, NC; ³Pathology, Wake Forest, Winston-Salem, NC; ⁴Pharmacy, Wake Forest, Winston-Salem, NC.
Elevated deceased donor (DD) serum creatinine (SCr) levels and prolonged cold ischemia time (CIT) are major independent reasons for kidney discard following organ recovery. Many…
2016 American Transplant Congress
Hospitalization and Living Donor Kidney Transplantation Among Waitlisted End Stage Renal Disease Patients in the US.
K. Newman,^1,2 A. Adams,² S. Pastan,² R. Lynch,² R. Zhang,¹ R. Patzer.^1,2
¹Emory University Rollins School of Public Health, Atlanta, GA; ²Emory University School of Medicine, Atlanta, GA.
Background: For End Stage Renal Disease Patients (ESRD) waitlisted for a deceased donor kidney, living donor kidney transplantation (LDKT) could allow for earlier transplantation and…
2016 American Transplant Congress
Interaction Between Kidney Tissue Proteome and Humoral Immunity in Antibody Mediated Rejection.
A. Konvalinka,¹ A. Chruscinski,² S. Kim,¹ K. Tinckam,¹ I. Jurisica,³ R. John.⁴
¹Medicine/Division of Nephrology, Toronto General Hospital, Toronto, ON, Canada; ²Medicine/Division of Cardiology, Toronto General Hospital, Toronto, ON, Canada; ³Medical Biophysics and Computational Science, University of Toronto, Toronto, ON, Canada; ⁴Pathology, Toronto General Hospital, Toronto, ON, Canada.
PURPOSE: Antibody-mediated rejection (AMR) is caused by antibodies against human leukocyte antigens (HLA) on graft endothelium, and non-HLA antibodies that target endothelial and epithelial proteins.…
2016 American Transplant Congress
ABO-Incompatible Living Kidney Transplantation at Multicenter Japanese Case Series: Evolution of Outcomes and Immunosuppressive Management.
K. Tanabe,¹ M. Okumi,¹ M. Furusawa,¹ K. Unagami,¹ T. Hirai,¹ H. Shirakawa,² T. Shimizu,¹ K. Omoto,³ M. Inui,¹ H. Ishida.¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan; ²Urology, Ohkubo Hospital, Tokyo, Japan; ³Urology, Todachuo General Hospital, Saitama, Japan.
[lsaquo]Background[rsaquo]ABO-incompatible living kidney transplantation (ABO-ILKT) has been performed to broaden the range of donor types used for living related kidney transplantation (LKT). Recently, ABO-ILKT has…
2016 American Transplant Congress
The Impact of Graft Thin Upper Pole Arterial Branch Ligation on Adult Living Donor Kidney Transplantation.
T. Hiramitsu, M. Okada, T. Yamamoto, M. Tsujita, N. Goto, S. Narumi, Y. Watarai.
Transplant and Endocrine Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan.
ObjectiveIn kidney transplanation, some upper pole branches are too thin to be reconstructed. The impact of graft thin upper pole arterial branch ligation on adult…
2016 American Transplant Congress
Acute Allograft Glomerulopathy: A Distinct Form of Cellular Rejection.
O. AL-Badri, M. Alexander, F. Cosio, L. Cornell.
Mayo Clinic, Rochester, MN.
Background: Acute allograft glomerulopathy (AAG) is an unusual glomerular lesion of allografts with endocapillary hypercellularity, markedly enlarged endothelial cells occluding the capillary lumen, and absence…
2016 American Transplant Congress
Long-Term Follow-Up of Renal Transplant Recipients (RTR) Treated with IVIG for De Novo Donor Specific Antibodies (DSA).
R. Knight,¹ S. Patel,¹ J. Loucks-DeVos,² S. Kuten,¹ A. Gaber.¹
¹Houston Methodist Hospital, Houston, TX; ²Kansas University Medical Center, Kansas City, KS.
Intravenous immune globulin (IVIG) may be beneﬁcial for pre-emptive treatment of de novo DSA in RTR without biopsy-proven acute rejection (AR). Herein, we present long-term…
2016 American Transplant Congress
Outcomes of Kidney Transplantation in Obese Recipients – Single Center Experience.
A. El-Hinnawi, A. Rajab, G. Bumgardner, L. Haj Naser, R. Plews, I. James, M. Henry, R. Pelletier.
Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.
Background: With the obesity epidemic, there is an increased prevalence of obesity amongst patients with ESRD. Controversy exists regarding post-transplant outcomes in obese kidney transplant…